A Bright Future for FISH - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Bright Future for FISH

  • By

  • Faidra Partheniou

  • November 16, 2026

  • 5 min

Share

Clinical Scorecard: The Evolving Clinical Role of FISH

At a Glance

CategoryDetail
ConditionUse of fluorescence in situ hybridization (FISH) in diagnostic cytogenetics, constitutional genetics, and hemato-oncology.
Key MechanismsFluorescence-labelled DNA probes hybridize to targeted chromosomal regions, enabling detection of copy-number changes, rearrangements, fusions, amplifications, and deletions in metaphase chromosomes or interphase nuclei.
Target PopulationPeople undergoing constitutional genetic evaluation or assessment for hematological malignancies, including suspected acute promyelocytic leukemia.
Care SettingDiagnostic cytogenetics and integrated diagnostic work-ups involving constitutional genetics or hematological malignancies.

Key Highlights

  • FISH provides targeted genomic information without the need for lengthy cell culture and can answer defined clinical questions quickly and reliably.
  • FISH is used alongside morphology, flow cytometry, karyotyping, PCR, and sequencing within comprehensive diagnostic work-ups.
  • The source describes FISH as particularly valuable when rapid information is required, karyotyping is unsuccessful, or only limited material is available.
  • In suspected acute promyelocytic leukemia, FISH can rapidly detect the PML::RARA fusion.
  • The source describes FISH as a targeted assay and an orthogonal method for confirming findings, complementing broader genomic approaches.

Guideline-Based Recommendations

Diagnosis

  • The article reports that the WHO Classification of Haematolymphoid Tumours calls for integration of morphological, immunophenotypic, molecular, and cytogenetic information for accurate diagnosis.
  • The article describes constitutional FISH use to identify microdeletions, aneuploidies, and cryptic subtelomeric translocations, and hematological FISH use to assess recurrent disease-associated abnormalities.

Management

  • The article describes FISH as one component of integrated diagnostic work-ups, rather than a replacement for broader genomic approaches.
  • The article states that targeted cytogenetic testing contributes to treatment-selection decisions when clinically actionable abnormalities are relevant.

Monitoring & Follow-up

    Risks

      Patient & Prescribing Data

      People evaluated for constitutional genetic abnormalities or hematological malignancies, including suspected acute promyelocytic leukemia.

      The article provides no prescribing regimens or patient-level treatment data. It states that FISH can identify abnormalities with diagnostic, prognostic, or therapeutic significance and that targeted cytogenetic testing contributes to treatment selection.

      Clinical Best Practices

      • The article describes FISH as a method for answering defined clinical questions requiring targeted chromosomal information.
      • The article identifies rapid information needs, unsuccessful karyotyping, and limited sample material as contexts in which FISH is particularly valuable.
      • The article describes interpretation of FISH alongside morphology, flow cytometry, karyotyping, PCR, sequencing, and other diagnostic information.
      • The article describes FISH as a targeted assay and an orthogonal method for confirming findings within integrated diagnostic pathways.

      Related Resources & Content

      Original Source(s)

      Related Content